ALS Untangled says Nuedexta may help bulbar function in ALS
Original source
Nuedexta (opens in a new tab)Nuedexta may improve bulbar function in people with amyotrophic lateral sclerosis (ALS), including those without pseudobulbar affect (PBA). A phase II trial found better patient-reported bulbar function, while another preliminary trial found improvement in bulbar physiology. Long-term effects remain unclear, and there is no evidence that Nuedexta slows ALS progression or extends survival.
Why this matters
Nuedexta could be considered for bulbar dysfunction in people with ALS, but its benefits may not last and treatment should be assessed regularly. It does not currently provide evidence of longer survival or slower disease progression. Cost and possible side effects matter, and it should be avoided by people with a known prolonged QT interval.
Limitations and context
This is an independent expert review, not a new primary research study. The source does not provide trial sizes or full study details. Evidence is mixed: one open-label study found no benefit after one year, and the long-term effect is uncertain. The review reports mild to moderate side effects and no severe side effects directly attributed to Nuedexta, but individual risks still require clinical assessment.